Mit biomedizinischer Forschung schneller zum Patienten: ForTra gGmbH gibt positive Förder-Bilanz bekannt
23 avr. 2024 04h00 HE
|
AKAMPION
Lücke zwischen Grundlagenforschung und klinischer Anwendung schließenMehr als 50 Prozent aller geförderten Projekte erhalten Anschlussfinanzierung Bad Homburg v.d. Höhe, 23.04.2024 – Die...
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track Record
23 avr. 2024 04h00 HE
|
AKAMPION
Closing the gap between basic research and clinical applicationMore than 50 percent of all funded projects received follow-up funding Bad Homburg v.d. Höhe, Germany, April 23, 2024 - ForTra gGmbH...
BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
03 avr. 2024 04h00 HE
|
AKAMPION
Further expansion of management expertise to accelerate BellaSeno´s market entry Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...
MetrioPharm stellt wissenschaftlichen Beirat aus erfahrenen Immunologie- und Pädiatrie-Experten vor
13 mars 2024 06h00 HE
|
AKAMPION
Die neuen Beiräte werden ihr Fachwissen in den Bereichen Immunologie, Pathologie, Entzündungsprozesse und in MetrioPharms Hauptindikation Duchenne-Muskeldystrophie einbringenDie Beiräte haben bereits...
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
13 mars 2024 06h00 HE
|
AKAMPION
The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy Advisors have previously collaborated with...
BellaSeno’s 3D-printed Resorbable Scaffold Successfully Used in Critical-Size Large Segmental Radius Bone Defect at Hannover Medical School
05 mars 2024 04h00 HE
|
AKAMPION
-- Trauma patient suffered from third degree open infected fracture of its radial shaft after injury by a bullet -- Graft vascularization was achieved by embedding vascular pedicle into the scaffold ...
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
20 févr. 2024 04h00 HE
|
AKAMPION
- Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria JERUSALEM, Israel, February 20, 2023 -- Omnix Medical, a...
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
06 févr. 2024 04h00 HE
|
AKAMPION
- First dose level rated as safe by independent Data Safety Monitoring Board- Second dose level to be administered according to plan- THE001 designed as targeted tumor treatment independent...
MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen
31 janv. 2024 05h00 HE
|
AKAMPION
Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare Wirksamkeit...
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
31 janv. 2024 05h00 HE
|
AKAMPION
Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional...